Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2 by D. Gnani et al.
OPEN
Focal adhesion kinase depletion reduces human
hepatocellular carcinoma growth by repressing
enhancer of zeste homolog 2
Daniela Gnani1, Ilaria Romito1, Simona Artuso2, Marco Chierici3, Cristiano De Stefanis1, Nadia Panera1, Annalisa Crudele1,
Sara Ceccarelli1, Elena Carcarino4, Valentina D’Oria5, Manuela Porru2, Ezio Giorda6, Karin Ferrari7, Luca Miele8, Erica Villa9,
Clara Balsano10, Diego Pasini7, Cesare Furlanello3, Franco Locatelli4,11, Valerio Nobili12, Rossella Rota4, Carlo Leonetti2 and
Anna Alisi*,1
Hepatocellular carcinoma (HCC) is the most common type of liver cancer in humans. The focal adhesion tyrosine kinase (FAK) is
often over-expressed in human HCC and FAK inhibition may reduce HCC cell invasiveness. However, the anti-oncogenic effect of
FAK knockdown in HCC cells remains to be clarified. We found that FAK depletion in HCC cells reduced in vitro and in vivo
tumorigenicity, by inducing G2/M arrest and apoptosis, decreasing anchorage-independent growth, and modulating the
expression of several cancer-related genes. Among these genes, we showed that FAK silencing decreased transcription and
nuclear localization of enhancer of zeste homolog 2 (EZH2) and its tri-methylation activity on lysine 27 of histone H3 (H3K27me3).
Accordingly, FAK, EZH2 and H3K27me3 were concomitantly upregulated in human HCCs compared to non-tumor livers. In vitro
experiments demonstrated that FAK affected EZH2 expression and function by modulating, at least in part, p53 and E2F2/3
transcriptional activity. Moreover, FAK silencing downregulated both EZH2 binding and histone H3K27me3 levels at the promoter
of its target gene NOTCH2. Finally, we found that pharmacological inhibition of FAK activity resembled these effects although
milder. In summary, we demonstrate that FAK depletion reduces HCC cell growth by affecting cancer-promoting genes including
the pro-oncogene EZH2. Furthermore, we unveil a novel unprecedented FAK/EZH2 crosstalk in HCC cells, thus identifying a
targetable network paving the way for new anticancer therapies.
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Hepatocellular carcinoma (HCC) is one of the most common
human cancers, accounting for 70–85% of primary liver
malignancies, and the third leading cause of cancer-related
death worldwide.1,2
Despite progress in cancer research and treatment, HCC
carries an extremely poor prognosis since it is often diagnosed
at advanced stages, restricting efficient therapeutic options
to either surgical resection or transplantation.3,4 Hence, it is
urgent to develop new and more effective therapeutic
strategies to defeat HCC. To achieve this goal, it is crucial to
deeply dissect molecular signaling pathways that drive and/or
control the development and progression of HCC.
It is widely accepted that hepatocarcinogenesis is char-
acterized by the accumulation of genetic and epigenetic
changes that occur during onset, promotion and progression
of HCC.5 Comparative genomic hybridization studies and
whole-genome sequencing have started to reveal the genetic
landscape of HCC, disclosing the most important oncogenic
pathways.6–8 Mutations in TP53 and β-catenin gene
(CTNNB1) frequently occur in HCC.6 Kan et al.8 found that
26.1% of HCCs harbor amplification of the human protein
tyrosine kinase 2 (PTK2) gene. This gene is located on 8q24
chromosome and codes for a 125-kDa non-receptor tyrosine
kinase named focal adhesion kinase (FAK).9,10
FAK is placed at the crossroads of many signaling pathways
that can promote cancer growth and metastasis. Indeed, FAK
is able to control, in a kinase-dependent manner, tumor cell
motility and invasion.11,12 Moreover, FAK can facilitate tumor
cell survival and regulate evasion of anti-tumor immunity
through kinase-independent scaffolding functions.13,14
In HCC, FAK over-expression has been even associated
with promotion of portal venous invasion and consequent
intrahepatic metastasis.15–18 Although liver homeostasis is not
affected in a mouse model with a specific deletion of FAK in
hepatocytes, FAK is required for c-Met/β-catenin-driven
hepatocarcinogenesis.19 Moreover, FAK is found to be a Met
direct target responsible for Met-induced invasion and
metastasis.19,20 Other promising studies showed that (i)
pharmacological inhibition of FAK reduces HCC invasion
in vitro and growth and metastasis in vivo; and (ii) silencing of
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FAK decreases cell invasion and viability in vitro.21,22
Altogether these findings corroborate the hypothesis of a
master role of FAK in the growth of HCC. However, the effect of
a specific genetic reduction of FAK levels in HCC cells in vivo
remains to be clarified and the potential crosstalk of FAK with
master genes involved in HCC is yet to be unveiled.
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Here, we found that stable silencing of FAK strongly reduced
both in vitro and in vivo HCC growth,confirming the key role of
this protein in hepatocarcinogenesis. We further demon-
strated that FAK depletion critically affected the transcription,
nuclear localization and activity on histone trimethylation at
lysine 27 (H3K27me3) of enhancer of zeste homolog 2
(EZH2), an epigenetic repressor and putative oncogene in
HCC.23–25 In addition, FAK, EZH2 and H3K27me3 were
concomitantly upregulated in human HCCs compared to non-
tumor livers. Importantly, we found that p53 and E2F2/3 were
key mediators of FAK-dependent effects on EZH2 expression/
activity.
In conclusion, here we describe a new molecular nexus
between FAK and EZH2 that controls HCC growth.
Results
FAK silencing reduces cell growth and induces apopto-
sis of HCC cells in vitro. To explore the functional role of
FAK in the control of HCC cell homeostasis, we established a
model of stable silencing of FAK by lentivirus-mediated
co-delivery of two short hairpin RNAs (shRNAs) specifically
targeting both 3′UTR and coding sequence of PTK2. HCC
cell lines (HepG2 and Huh6) silenced for FAK (shFAK)
exhibited a reduction of FAK mRNA and protein compared to
the cells infected with a non-targeting shRNA vector (Control)
(Supplementary Figures S1a and b). The upregulation of the
FAK-target gene E-Cadherin (CDH1) confirmed the reduction
of FAK activity (Supplementary Figures S1a and b).
HCC cells transduced with FAK shRNAs had a slower
growth rate and a decreased DNA synthesis with respect to
control cells (Supplementary Figure S1c, Figure 1a). More-
over, as a counterweight to the decrease of cells populations in
G0/G1 and S phase, the proportion of cells in G2/M phasewas
higher in shFAK than in control HCC cells (Figure 1b)
coherently with an increased early apoptosis (Figure 1c).
HCC cells stably silenced for FAK also exhibited a significant
decrease in colony formation with respect to control cells
(Supplementary Figure S1d).
Reduced proliferation rate and apoptosis induction in HCC
cells silenced for FAK were confirmed by the decreased
activity of signaling pathways commonly involved in these
processes. In fact, the expression of the serine 380
phosphorylated/inactive form of phosphatase and tensin
homolog (PTEN) and of its target serine 473 phosphory-
lated/active form of AKT decreased in shFAK cells (Figure 1d,
Supplementary Figure S1e). Moreover, the protein expression
levels of total and phosphorylated/active form of ERK1/2 and
p38 mitogen activated protein kinase were reduced by
knockdown of FAK as well (Figure 1e, Supplementary
Figure S1f). Finally, p21 increase and the appearance of the
cleaved form of caspase-3 were also observed in shFAK cells,
confirming G2/M arrest and apoptosis reported before
(Figure 1f).
FAK silencing reduces growth of human HCC in mouse
xenografts. The role of FAK in in vivo HCC growth was
tested in orthotopic and heterotopic tumor-xenograft models,
using HepG2 cells engineered with a luciferase reporter
(HepG2-luc).26
HepG2-luc-CTRL and HepG2-luc-shFAK cells were
injected intramuscularly in nude mice or directly into the liver
of NOD/SCID mice, and tumor growth was monitored at
different time points by bioluminescence imaging. Notably,
NOD/SCID mice showed a very significant reduction of tumor
growth generated through intrahepatic injection of HepG2-luc-
shFAK as compared to HepG2-luc-CTRL xenografts
(Figures 2a and b, Supplementary Figure S2a). The anti-
tumor effect of FAK silencing was also confirmed by the
intramuscular injection of HCC cells in nude mice
(Supplementary Figure S2b).
Tissue analysis confirmed that the expression of FAK at
54 days post injection (p.i.) was drastically reduced in
intrahepatic tumors derived from FAK-silenced HepG2 cells
(Figure 2c). Concomitantly, FAK knockdown caused, in the
tumor area, downregulation of the expression of proliferating
cell nuclear antigen (Figure 2d), a marker of cell prolife-
ration in HCC,27 upregulation of caspase-3 (Supplementary
Figure S2c), and over-expression of E-Cadherin protein and
mRNA (Supplementary Figures S2d and e).
FAK regulates the expression of cancer-related genes in
HCC cells. To gain mechanistic insights into the role of FAK
in HCC, we sought to determine FAK-dependent expression
of cancer genes in HepG2 cells silenced or over-expressing
PTK2 gene, respectively called shFAK and PTK2. To this
end, we performed the analysis of 624 cancer genes with an
Open Array Real-Time PCR platform. Gene expression
profile analysis led to the identification of differentially up- or
downregulated genes upon FAK depletion or over-expression
(Figures 3a and b, Supplementary Tables S1 and S2).
As shown by Venn diagram (Figure 3c), among the genes
downregulated after FAK knockdown, we identified a set of
158 potential direct/indirect specific targets being also
upregulated upon FAK over-expression. Moreover, we found
a set of 86 genes that are either upregulated by FAK silencing
or downregulated under FAK over-expression (Figure 3d).
These genes are involved in the control of several cellular
processes, comprising signal transduction, immune response,
cell cycle and gene expression regulation, metabolism and
Figure 1 FAK depletion inhibits growth and promotes apoptosis in HCC cells. (a) Cell proliferation assayed via a BrdU incorporation kit and expressed as Europium (Eu)
counts in Control and shFAK HepG2 and Huh6 cells. Values are mean±SD (*Po; 0.05;**Po0.01; n= 4). (b) Distribution of Control and shFAK HepG2 and Huh6 cells in G0/
G1, S and G2/M phase of the cell cycle by propidium iodide (PI) staining and flow cytometric analysis. Values are plotted as mean± SD (**Po0.01; n= 3). (c) Percentage of
apoptotic Control and shFAK HepG2 and Huh6 cells measured by Annexin Vand flow cytometry. Values are plotted as mean± SD (*Po0.05; n= 3). (d) Representative western
blots (WB) for PTEN and p-PTEN, and for AKTand p-AKT in Control and shFAK HepG2 and Huh6 cells. (e) Representative WB for ERK1/2 and p-ERK1/2, and for p38 and p-p38
in Control and shFAK HepG2 (n= 3) and Huh6 cells (n= 2). (f) Representative WB for p21 and caspase-3 in Control and shFAK HepG2 (n = 2) and Huh6 cells (n = 2). GAPDH
is reported as a loading control
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hemostasis (Figures 3e and f). Moreover, from the analysis of
genes downregulated by FAK silencing and upregulated by
FAK over-expression, some epigenetic regulators of gene
expression, such as EZH2, have emerged for the first time as
direct/indirect potential targets of FAK.
FAK modulates EZH2 expression and trimethylation of
histone H3 at lysine 27 in HCC cells. A previous study
demonstrated that over-expression of EZH2 correlated with
upregulation of total or phosphorylated FAK predicting a more
aggressive behavior in endometrial carcinoma.28 In HCC, the
relationship between FAK and EZH2 has never been
investigated before. Thus, we evaluated the mRNA and
protein expression of EZH2 either in a condition of FAK
depletion or over-expression in HCC cells. Our results
confirmed that FAK knockdown reduced both EZH2 mRNA
and protein levels (Figures 4a and b). Conversely, FAK over-
expression increased EZH2 mRNA levels (Supplementary
Figure S3a).
EZH2 is the core catalytic component of the Polycomb
repressive complex 2 (PRC2), responsible for gene repression
through trimethylation of lysine 27 on histone H3 (H3K27me3)
of target gene promoters.29 We found that shFAK HCC cells
exhibited a strong reduction of H3K27me3 total levels
Figure 2 FAK depletion impairs HCC growth in mouse xenograft models. (a) Representative imaging of NOD/SCID mice bearing intrahepatic tumors from respectively
HepG2-luc-CTRL (CTRL) and HepG2-luc-shFAK cells (shFAK). (b) Quantitative analysis of luciferase activity in vivo at various time points. The luminescence signals are
expressed as mean± SD of total flux of photon/sec/cm2/steradian (p/s/cm2/sr) (**Po0.01; ***Po0.001; n= 6). (c) Representative IHC of FAK expression in liver samples (tumor
and non-tumor) from CTRL and shFAK xenografts at 54 days p.i. (×20 magnification). (d) Representative IF of PCNA expression in intrahepatic tumor samples from CTRL and
shFAK xenografts at 54 days p.i. (×20 magnification)
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Figure 3 Cancer-associated genes are influenced by FAK expression. (a) Heatmap representation of the expression of cancer-related genes in HepG2 cells upon FAK
silencing compared to control (shFAK versus Control). (b) Heatmap representation of the expression of cancer-related genes in HepG2 cells upon FAK over-expression compared
to empty vector (PTK2 versus Vector). (c) Venn diagram showing the overlapping of genes downregulated upon FAK depletion with those upregulated upon FAK over-expression.
(d) Venn diagram showing the overlapping of genes upregulated upon FAK depletion with those downregulated upon FAK over-expression. (e) Bar plot of the 10 most abundant
pathways for genes downregulated upon FAK silencing. (f) Bar plot of the 10 most abundant pathways for genes upregulated upon FAK silencing
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associated with a decrease of nuclear EZH2 compared to
control cells (Figures 4c and d). As expected, miR-200b, a
well-described target of EZH2,30 was upregulated by FAK
silencing (Supplementary Figure S3b).
According to in vitro data, immunostaining for EZH2 and
H3K27me3 was substantially reduced (Supplementary
Figures S3c and d) in tumors from HepG2-luc-shFAK NOD/
SCID mice with respect to HepG2-luc-CTRL animals.
Furthermore, the analysis of tissue arrays, which contained
16 cases of HCC, in duplicates, with corresponding normal
non-tumor zone from the same patients as controls, revealed
concomitant upregulation of FAK, EZH2 and H3K27me3 in
Figure 4 FAK silencing influences EZH2 expression and activity in HCC cells. (a) Relative mRNA expression of EZH2 gene as measured by quantitative Real-Time PCR
(qRT-PCR) in Control and shFAK HepG2 and Huh6 cells. Values are expressed as fold mean±SD (*Po0.05; ***Po0.001; n= 3). (b) Representative WB and densitometric
quantification for EZH2 protein in Control and shFAK HepG2 and Huh6 cells. GAPDH is reported as a loading control (***Po0.001; n= 3). (c) Representative WB of H3K27me3
in Control and shFAK HepG2 and Huh6 cells. GAPDH is reported as a loading control (n= 2). (d) Representative WB of cytosolic and nuclear EZH2 protein in Control and shFAK
HepG2 and Huh6 cells. GAPDH and C23 are reported as loading controls (n= 2). (e) Average fluorescence intensity calculated for FAK, EZH2 and H3K27me3 in liver tumor
(HCC) and non-tumor (Normal) samples from the same patients (n= 16). Values are plotted as mean± SD (***Po0.001). (f) Average fluorescence intensity calculated for FAK,
EZH2 and H3K27me3 in HCC samples according to tumor staging. Values are plotted as mean±SD (*Po0.05; **Po0.01). (g) Heatmap representation of the expression of
FAK, EZH2 and H3K27me3 in Normal tissues and HCC according to grade of disease (I, II, II). This image was generated by using the online tools provided by CIMminer
(http://discover.nci.nih.gov/cimminer/home.do)
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tumor specimens (Figure 4e). Noteworthy, the increase of all
three proteins correlate with the severity of the disease in
terms of tumor staging, differentiation and presence of
metastasis (Figure 4e–g, Supplementary Figures S3e and f,
Supplementary Table S3).
p53 mediates FAK-dependent effects on EZH2 expres-
sion and activity. To unveil the molecular link connecting
FAK to EZH2, we investigated different pathways that have
previously been described as regulators of EZH2 expression
and activity.
FAK depletion did not affect expression levels of miR-101
(Supplementary Figure S4a), which is known to act as a
repressor of EZH2 transcription.31 Interestingly, silencing of
FAK in HepG2 cells resulted in upregulation of both total and
phosphorylated p53 (Figures 5a and b). A previously
published study demonstrated that p53 over-expression
resulted in the repression of EZH2 transcription.32 To test
the hypothesis of a p53-driven EZH2 regulation in our model,
we performed a Chromatin Immunoprecipitation (ChIP) assay
using a specific anti-p53 antibody to precipitate chromatin
fragments from either control or FAK-depleted HepG2 cells. To
this purpose, specific primers have been designed around the
CpG Island in the promoter region of EZH2 (Supplementary
Figures S4b and c). Increased p53 binding to the EZH2
promoter in a region without p53 binding motifs confirmed our
hypothesis (Figure 5c and Supplementary Figure S4d). The
role of p53 in mediating FAK-dependent regulation of EZH2
was confirmed by transient silencing experiments showing
that p53 silencing in a condition of FAK depletion caused
upregulation of EZH2 gene expression (Figures 5d and e).
Experiments performed in Huh7.5 p53 functionally defective
cells further confirmed the relevance of p53 in shFAK-
dependent reduction of HCC cell growth and EZH2 regulation.
The efficiency of FAK silencing was similar to that observed in
HepG2 cells (Supplementary Figures S5a and b), but its effect
on EZH2 mRNA and protein was less evident than in HepG2
cells (Supplementary Figures S5c and d). Moreover, FAK
depletion also induced a slight reduction of proliferation rate
and apoptosis in Huh7.5 cells (Supplementary Figures S5e
and f).
FAK silencing affects EZH2 transcription/activity by
E2F. To characterize additional mediators of FAK-related
EZH2 transcriptional downregulation, we tested the potential
role of E2F, which is able to bind EZH2 promoter to turn on its
transcription.33 ChIP assay demonstrated that FAK-depleted
HepG2 cells displayed a decrease in the binding of both
E2F2 and E2F3 to EZH2 promoter with respect to control
HepG2 cells (Figures 6a and b). These results were
Figure 5 p53 is a mediator of FAK silencing effects on EZH2 in HepG2 cells. (a) Representative WB and densitometric quantification for p53 in Control and shFAK HepG2
cells. GAPDH is reported as a loading control. Values are mean±SD of at least three independent experiments (**Po0.01; n= 3). (b) Representative IF of serine 15
phosphorylated form of p53 in Control and shFAK HepG2 cells. DRAQ5 was used to stain nuclei (×60 magnification). (c) ChIP assays for p53 at the EZH2 promoter in Control and
shFAK HepG2 cells. Values are expressed as percentage of input DNA of three independent experiments. IgG was used as negative ChIP control. (d) Relative mRNA expression
of EZH2 gene as measured by qRT-PCR in Control and shFAK HepG2 cells after transient silencing with siC or sip53. Values are expressed as fold mean± SD (***Po0.001;
n= 3). (e) Relative mRNA expression of TAp53 gene as measured by qRT-PCR in Control and shFAK HepG2 cells after transient silencing with siC or sip53. Values are
expressed as fold mean± SD (***Po0.001; n= 3)
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confirmed in Huh7.5 cells (Figures 6c and d), thus suggesting
that FAK/E2F/EZH2 is totally p53 independent.
It is well known that E2F activity on target genes, such as
EZH2, was shown to be constrained by the binding to
retinoblastoma protein (pRb).33,34 We found that FAK
depletion in HCC cells increased the expression of hypopho-
sphorylated pRb (Figure 6e). This effect of FAK silencing
on pRb could depend on the well-known ERK1/2-mediated
relationship between FAK and G1-Phase regulators,
such as cyclin D1/cdk4-6 complex and p16INK4,
which may influence pRb phosphorylation status.35,36 Accord-
ingly, under FAK depletion we found a downregulation of
phosphorylated cdk level (Figure 6f), and an increase of
p16INK4 gene (CDKN2A) expression (Supplementary
Figure S6a).
As we previously observed that FAK silencing causes a
reduction of EZH2 nuclear localization and activity, we
supposed that a physical interaction between these two
proteins might also occur. Our preliminary data showed that
FAK co-precipitated with EZH2, and that FAK knockdown in
HepG2 cells reduced this interaction, suggesting also a
possible functional physical interaction. (Supplementary
Figures S6b and c).
NOTCH2 is a target gene for the FAK/EZH2 network in
HCC cells. Among all the genes that could be controlled by
FAK/EZH2 network, we explored NOTCH2, which has
already been reported to be under the control of EZH2 in
HCC.37 As previously observed with gene expression
profile by OpenArray, FAK silencing caused upregulation of
NOTCH2 mRNA levels in HepG2 cells (Supplementary
Tables S1). Coherently, upon FAK silencing, we found a
reduction of EZH2 and H3K27me3 enrichment on NOTCH2
promoter (Figure 7a). Transient over-expression of an
exogenous EZH2 in FAK-silenced HepG2 cells
(Supplementary Figure S7a) rescued the expression levels
of NOTCH2 (Figure 7b). In addition, EZH2 forced upregula-
tion reverted the expression of other genes modulated by
FAK depletion (Supplementary Figures S7b and c,
Supplementary Table S4). From a functional point of view,
Figure 6 FAK silencing in HCC cells affects E2F2 and E2F3 binding to EZH2 promoter. ChIP assay of E2F2 (a) and E2F3 (b) on the EZH2 promoter in Control and shFAK
HepG2 cells. ChIP assays of E2F2 (c) and E2F3 (d) on the EZH2 promoter in Control and shFAK Huh7.5 cells. Values are expressed as percentage of input DNA of three
independent experiments. IgG was used as negative ChIP control. (e) Representative WB for pRb in Control and shFAK HepG2 and Huh7.5 cells (n= 3). (f) Representative WB
for phosphorylated cdks (p-cdks) in Control and shFAK HepG2 and Huh7.5 cells. α-tubulin is reported as a loading control (n= 3)
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Figure 7 FAK silencing affects EZH2 dependent repression of NOTCH2 transcription. (a) ChIP assays for EZH2 and H3K27me3 at the NOTCH2 promoter in Control and
shFAK HepG2 cells. Data are expressed as fold enrichment of three independent experiments repeated in duplicate. (b) Relative mRNA expression of NOTCH2 gene as
measured by qRT-PCR in Control+pcDNA3, shFAK+pcDNA3 and shFAK+EZH2 HepG2 after 72 h from plasmid transfection. Values are expressed as fold mean± SD of three
independent experiments repeated in triplicate (*Po0.05; ***Po0.001). (c) Distribution of shFAK+pcDNA3 and shFAK+EZH2 HepG2 in G0/G1, S, G2/M and SubG1 phase of
the cell cycle by PI staining and flow cytometric analysis. Values are plotted as mean± SD (**Po0.01; n= 3). (d) Percentage of apoptotic shFAK+pcDNA3 versus shFAK+EZH2
HepG2 cells measured by Annexin Vand flow cytometry. Values are plotted as mean± SD (**Po 0.01; n = 5). (e) Distribution of shFAK+Vector and shFAK+PTK2 HepG2 in G0/
G1, S, G2/M and SubG1 phase of the cell cycle by PI staining and flow cytometric analysis. Values are plotted as mean± SD (**Po0.01; n= 3). (f) Percentage of apoptotic of
shFAK+Vector and shFAK+PTK2 HepG2 cells measured by Annexin V and flow cytometry. Values are plotted as mean±SD (**Po 0.01; n= 3). (g) Relative mRNA expression
of FAK, EZH2 and NOTCH2 genes as measured by qRT-PCR after 48 h from plasmid transfection (empty or PTK2 vector) in Control and shFAK HepG2 cells (**Po0.01;
*Po0.05; n= 3)
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however, EZH2 rescue was able to reduce G2/M phase arrest
and apoptosis (Figures 7c and d), and to partially counteract
the anchorage-independent growth impaired by FAK silen-
cing (Supplementary Figure S7d).
A further confirmation that FAK/EZH2 network is crucial for
the regulation of HCC cell homeostasis and the effect on target
genes, such as NOTCH2, was obtained by re-expressing FAK
in HCC cells. In fact, FAK rescue decreased G2/M phase
Figure 8 Pharmacological inhibition of FAK mimics the effect of FAK silencing confirming FAK/EZH2 network in HCC cells. (a) Percentage of apoptotic HepG2 and Huh7.5
cells after 48 h of treatment with DMSO (Vehicle), 0.5 μM or 1 μM PND 1186 measured by Annexin V and flow cytometry. Values are plotted as mean± SD (*Po0.05;
**Po0.01; versus Vehicle, n = 3). (b) Representative WB for p21 and caspase-3 in HepG2 and Huh7.5 cells after 48 h of treatment with DMSO (0), 0.5 μM or 1 μM PND 1186.
β-tubulin is reported as a loading control (n= 2). (c) Relative mRNA expression of EZH2 and NOTCH2 genes as measured by qRT-PCR in HepG2 and Huh7.5 cells after 48 h of
treatment with DMSO (Vehicle), 0.5 μM or 1 μM PND 1186 (*Po0.05; **Po0.01; versus Vehicle, n = 3). (d) In HCC cells, upregulated FAK causes inhibition of p53 expression,
which normally hampers EZH2 production, while in the meantime induces E2F transcriptional activity favoring EZH2 over-expression. The consequent transcriptional repression
of EZH2 target genes supports the tumorigenic cell features. (e) Conversely, the depletion of FAK in the same cellular context results in the expression of p53 and the blockade of
E2F functions, critically reducing the EZH2-dependent epigenetic silencing of target genes, thus impairing tumor growth. The dotted blue line indicates additional potential
regulations of EZH2 functions by FAK physical interaction
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arrest and apoptosis, and caused upregulation of EZH2
mRNA and downregulation of NOTCH2 mRNA in FAK-
depleted HepG2 (Figures 7e–g) and Huh7.5 cells
(Supplementary Figures S7e–g).
Inhibition of FAK activation induces cell cycle arrest at
the G0/G1 phase in HCC cells. In order to evaluate if the
observed pro-apoptotic effects depend on FAK activity we
treated HepG2 and Huh7.5 cells with PND-1186 that was
able to inhibit Tyr-397 phosphorylation of FAK.38
HCC cells were exposed to 0.5 μM and 1 μM of PND-1186.
The treatment with PND-1186 decreased cell proliferation rate
(Supplementary Figure S8a) by significantly inducing G0/G1
phase arrest and apoptosis at 48 h (Supplementary
Figure S8b,Figure 8a). Accordingly, PND-1186 treatment
caused downregulation of FAK Tyr-397 phosphorylation and
cyclin D1 amount (Supplementary Figures S8c and d) and
increased the expression of both p21 and cleaved caspase-3
at 48 h (Figure 8b). As expected, 1 μM PND-1186 significantly
downregulated EZH2 mRNA and upregulated NOTCH2
expression (Figure 8c).
Discussion
Here, we present data demonstrating that specific depletion of
FAK by genetic silencing slows down/reducesHCC cell growth
in vitro and in vivo. Thus, we unveil a new molecular crosstalk
between FAK and the histone methyl transferase EZH2
(Figures 8d and e) that may explain the FAK knockdown-
dependent biological effects in HCC.
The anti-tumorigenic in vitro effect of FAK depletion
depended on the induction of apoptosis that reduced the
proliferation rate by the activation of specific signaling path-
ways. In fact, the signaling of PTEN/AKT, and the activity of
pro-mitogenic activated protein kinases were affected by FAK
silencing in line with their already described role on HCC
pathogenesis.39–42 Furthermore, HCC cells with FAK deple-
tion displayed an over-expression of p21, involved in the G2/M
cell cycle arrest, which can precede apoptotic response.42
Accordingly, FAK silencing in human HCC cells was able to
decrease their intrahepatic growth in immune-deficient mice.
Our data suggest that partial FAK knockdown may achieve
these effects regulating the expression of several cancer-
related genes. In fact, the analysis of common dysregulated
genes, by either silencing or exogenous over-expression of
FAK, led to the identification of different genes that can be
flagged as new potential direct/indirect targets of FAK. Among
these, we identified the gene encoding for EZH2, which was
downregulated by FAK silencing in in vitro and in vivo HCC
models. Moreover, the modulatory effect of FAK depletion is
not only restricted to EZH2 transcriptional regulation but also
encompasses its role onH3K27me3 activity. The parallel trend
of FAK and EZH2 well correlated with their already-reported
tumor promoting activity on HCC.20,25 In fact, FAK silencing
significantly reduced the well-characterized tumor-suppressor
miR-200b, as previously reported by Au et al.25 in EZH2-
knockdown cell lines and primary HCC samples. Furthermore,
since both FAK and EZH2 downregulation may interfere with
autophagy in cancer cells,43,44 it is plausible that also this
mechanism may contribute to cell cycle arrest and apoptosis
in our system, but further studies are required to confirm or
disprove this hypothesis.
To our knowledge, only few evidences of EZH2 and FAK
connection have been reported so far. A recent study
demonstrates that FAK activity is influenced by EZH2 in
dendritic cells,45 while concomitant over-expression of these
two proteins was also reported in endometrial carcinoma
tissues.28 Accordingly, in our experiments, tumor area from
human HCC samples exhibited concomitant over-expression
of FAK, EZH2 and H3K27me3 compared to non-tumor zones.
Further studies on large cohorts of pediatric and adult HCCs
are necessary to explore the correlation of these three
interactors with severity and progression of disease.
EZH2 function in transcriptional repression via H3K27me3-
has been extensively investigated.46 However, themechanism
by which EZH2 is regulated, in response to intrinsic cell-cycle
signals or to extrinsic inputs, remains elusive. Although
miR-101 has been shown to be a crucial repressor of EZH2
transcription,31 the FAK-dependent EZH2 down-modulation in
HCC cells seems to be independent of this mRNA requiring
alternative molecular factors.
A previous study showed that p53 over-expression resulted
in the EZH2 transcriptional repression.32 Our results demon-
strated that an inactive p53 reduced most of the FAK-
dependent effects on HCC cell growth, apoptosis and EZH2
regulation suggesting a role of p53 as a crucial mediator of
FAK/EZH2 crosstalk. Indeed, we found an increased binding
of p53 to EZH2 promoter region upon FAK silencing,
confirming the upstream role of p53 on EZH2 also in HCC
cells. However, as FAK depletion preserves a quote of its
reducing ability on EZH2 transcription and pro-apoptotic
effects even in a condition of p53 loss of function, it is likely
that additional factors may connect FAK to EZH2 and
apoptosis. E2F might be one of these players since it is
involved in the control of cell proliferation and may bind EZH2
gene promoter, positively regulating its transcription.33 In line
with our hypothesis and literature data,33–35 we found that
E2F2/3 binding to EZH2 promoter is impaired upon FAK
silencing in HCC cells and probably as a consequence of
decrease of pRb phosphorylation and increase of E2F2/3
retention. In addition, our preliminary results provide evidence
that FAK may physically associate with EZH2 at least in
p53-functional HCC cells, suggesting an additional mechan-
ism of interaction between these two proteins, which deserves
further consideration.
The inhibition of FAK in HCC cells might upregulate
NOTCH2 gene expression by reducing the enrichment of
EZH2 and H3K27me3 at NOTCH2 promoter. Gao et al.37
previously reported the repression activity of EZH2 on
NOTCH2 in HCC. Accordingly, we found that the expression
of some genes upregulated by FAK silencing, such as
NOTCH2, was downregulated again under EZH2 and PTK2
rescue in FAK-depleted HCC cells, which exhibited apoptosis
reduction and unlocking of G2/M-phase arrest.
Finally, the use of the specific FAK inhibitor PND-118647
demonstrated that the impair of FAK autophosphorylation at
tyrosine 397 was able to reduce HCC cell growth via induction
of G0/G1 arrest and apoptosis, and downregulation of EZH2
gene expression with consequent upregulation of NOTCH2
gene expression. However, the effect of FAK activity inhibition
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on HCC growth appears to be not as strong as that observed
by FAK silencing, thus suggesting that the G2/M arrest and
consequent apoptosis might be mainly associated to the
scaffold function of FAK.
Our results also highlight that disruption of FAK/EZH2
network may induce apoptosis by both a p53-mediated and
p53-independent mechanism, though further studies are
required to investigate the performance of FAK/EZH2 network
on the other modulated genes.
In conclusion, our results complete the picture from previous
studies on the key role of FAK as tumor promoting gene in
HCC,20–22 but more importantly, provide the first evidence of a
connection between FAK and EZH2, introducing a new protein
network that is active in the control of HCC cell proliferation. In
this FAK/EZH2 nexus, p53 and E2F may act as mediators
while NOTCH2, and other unexplored genes, would act as
potential target genes.
All our findings may have strong therapeutic implications. In
fact, the effects, resulting from FAK-dependent deregulation of
EZH2 transcriptional repression of specific targets, may
converge to reinforce HCC sensitivity to selective FAK
inhibition possibly reducing both local tumor growth and
distant metastasis. Furthermore, since Azzariti et al. have
recently reported48 a novel mechanism by which Sorafenib
may induce HCC cell resistance through Laminin-332/α3
integrin-dependent escape of FAK from ubiquitination and
consequent degradation, it is plausible that pharmacological
inhibition of FAK may also enhance Sorafenib therapeutic
performance. This information provides a proof-of-concept
that drugs acting against FAK and EZH2, either those already
approved by Food andDrug Administration or new ones, could
represent a therapeutic option for HCC.11,49
Materials and Methods
Cell lines and cultures. The human HepG2 cell line was purchased from
ATCC (Manassas, VA, USA) that provided certificated authentication, and the Huh6
and HuH7.5 cell lines were provided by a collaboration with Dr. Balsano that
performed authentication in 2014. Cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% FBS, 1% L-glutamine, 1% penicillin/streptomycin at
37 °C in 5% CO2 in a 95% humidified atmosphere. All cell lines were intermittently
tested for the presence of mycoplasma.
To follow tumor growth in vivo, HepG2 cells were transfected with an inducible
plasmid encoding firefly luciferase and selected with G418 to produce HepG2-
Luc cells.
shRNA lentiviral transduction. MISSION shRNA Lentiviral Transduction
Particles (Sigma Aldrich, Poole, UK) were used to knockdown PTK2 in HepG2 and
Huh7.5 cell lines. TRC1-pLKO.1-puro vector containing a short hairpin insert with
gene-specific sequence was used for cell transduction according to the
manufacturers’ protocol in presence of hexadimethrine bromide (8 μg/ml), to
enhance transduction efficiency. Sequences of inserts in shRNA constructs
targeting the PTK2 gene (3UTR and CDS) are 5′-CCGGGAGAGCATGAA
GCAAAGAATTCTCGAGAATTCTTTGCTTCATGCTCTCTTTTT-3′ and 5′-CCGGGT
CTAGAAATACGGCGATCATCTCGAGATGATCGCCGTATTTCTAGACTTTTTG-3′ re-
spectively. Pilot studies were performed to define the optimal multiplicity of infection
without cell toxicity (MOI= 4). In addition, MISSION pLKO.1-puro Non-Target
shRNA Control Transduction Particles (Sigma Aldrich) were used as negative
control and reference for interpretation of knockdown. Stable gene knockdown was
established by cellular resistance to puromycin (5 μg/ml). Obtained polyclones were
crio-preserved, tested for FAK mRNA and protein expression and used for the
experiments.
Plasmids and siRNA transfection. Details on cell transfection, plasmids
and siRNAs were provided in Supplementary Experimental Procedures.
Animals. All procedures involving mice and care were performed in compliance
with our institutional animal care guidelines and following national and international
directives (D.L. 4 March 2014, no. 26; directive 2010/63/EU of the European
parliament and of the council).
CD-1 nude (12 animals) and NOD/SCID (14 animals) male mice 6–8 weeks old
were used (Charles River laboratories, Calco, MI, Italy). HepG2-Luc silenced or not
for FAK cells were injected intramuscularly in nude mice at 3 × 106 cells/mouse or in
the liver of NOD/SCID mice at 106 cells/mice. Intramuscular tumors were measured
twice per week, and tumor sizes were calculated using the following formula:
V= (a/b2)/2, where a is the largest dimension and b the smallest. Mice bearing
intramuscularly or intrahepatic tumors were imaged using the IVIS imaging system
200 series (Caliper Life Sciences, Hopkinton, MA, USA). Briefly, mice were
anesthetized and then were injected intraperitoneally with 150 mg/kg D-luciferin and
then imaged. At the end of the experiments, mice were killed; livers were collected
and imaged. Data were acquired and analyzed using the living image software
version 3.0 (Caliper Life Sciences).
Cell growth. Cell proliferation was assessed by trypan blue exclusion assay.
Briefly, for each experiment Control and shFAK HCC cells were seeded in T25
flasks in triplicate and cultured. At 24, 48, 72, 96 and 120 h cells were trypsinized
and the number of viable cells was counted under a light microscope. At least four
counts were performed per flask on three different experiments.
Bromodeoxyuridine-based cell proliferation assay. Control or
shFAK HCC cells were plated in a 96 microplate well and allowed to grow. The
DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) Cell
Proliferation Assay was performed following the manufacturer’s instructions
(PerkinElmer, Waltham, MA, USA) as previously described.50
Cell cycle analysis. Cell cycle phase distribution was analyzed at 24 h from
post-starvation serum replacement by flow cytometry using PI staining (Sigma
Aldrich). Briefly, Control or shFAK HCC cells were collected by trypsinization,
washed with PBS, then fixed in a solution of a cold 4 : 1 methanol/acetone solution.
Cells were first incubated with RNase A at +37 °C then stained with a solution
containing 100 μg/ml PI, at +37 °C for 20 min. Stained nuclei were analyzed for
DNA-PI fluorescence using a Becton Dickinson FACSCanto II flow cytometer
(Becton-Dickinson, Milan, Italy). Resulting DNA distributions were analyzed for the
proportions of cells in G0/G1, S phase, and G2/M phases of the cell cycle by DiVa
Software, version 6.3 (Becton-Dickinson).
Apoptosis. Apoptosis was assessed by Annexin V staining at 24 h from post-
starvation serum replacement. Briefly, cells were washed in PBS and re-suspended
in Annexin Binding Buffer (10 mmol/L HEPES pH 7.4, 140 mmol/L NaCl, and
2.5 mmol/L CaCl). Cells were then stained with 0.5 mg/mL Annexin V-FITC (Becton-
Dickinson, Milan, Italy) for 15 min before analyzing. Acquisition and analysis were
carried out on a Becton Dickinson FACSCanto II flow cytometer, using DiVa
Software, version 6.3.
Analysis of mRNAs and protein expression. Details for the analysis of
mRNA and protein expression are provided in the Supplementary Experimental
Procedures.
Soft agar assay. Anchorage-independent growth was determined by soft agar
assay. A base layer of complete culture medium in 1% agar was established in 60-
mm culture dishes. HCC cells were plated at 1 × 105 cells per dish in the top layer
composed of the same culture medium and 0.7% agar mixture. Growth medium
was refreshed every 2–3 days. After 28 days, colonies were stained with Crystal
Violet (Sigma Aldrich) and counted under a light microscope.
Immunohistochemistry and immunofluorescence. Immunohisto-
chemical and immunoflorescent staining on human and murine livers were
performed as previously reported.51 Major details are available in the
Supplementary Experimental Procedures.
Open array. A pre-designed TaqMan OpenArray Human Cancer Panel (Life
Technologies, Thermo Fisher Scientific Corporation, Foster City, CA, USA) was
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used to assess the effect of FAK depletion or over-expression in HepG2 cells on a
signature panel of 624 well-defined genes validated for the characterization of
cancers, plus 24 endogenous control genes. cDNAs were loaded onto the Open
Array platform and run as recommended by the manufacturer on the QuantStudio
12K Flex Real-Time PCR system (Life Technologies, Thermo Fisher Scientific
corporation). Details for the analysis of gene profile are provided in the
Supplementary Experimental Procedures.
Heatmaps generation and pathway enrichment. Relative quantity
(RQ) expression values above 20 were considered unreliable and thus discarded.
For visualization purposes, heatmaps were generated by the function heatmap.2 in
the R library gplots starting from log2(RQ+e), where e= 0.01 was added to avoid
infinite values when RQ= 0.
For Venn diagrams, genes were considered ‘upregulated’ (resp. ‘downregulated’) if
RQ41 (resp. RQo1). Pathway analysis was conducted by querying Reactome
annotations using the R/Bioconductor library reactome.db.52,53
ChIP assay. ChIP assay protocol is described in Supplementary Experimental
Procedures.
Antibody list. All used antibodies were validate for the appropriate application
(Supplementary Table S5).
Drug treatment and cell proliferation assay. PND-1186 (Selleck
Chemicals, Houston, TX, USA) was dissolved in dimethyl sulfoxide and stored at
− 80 °C until time of use. Cell proliferation was then assessed using Cell
Proliferation Kit II (XTT) (Roche Applied Science, Indianapolis, IN, USA) according
to the manufacturer’s recommendations.
Statistical analysis. The data are presented as mean± SD. Comparisons
were made between means from at least three independent experiments repeated
in duplicate. Statistical differences were analyzed using the Student t-test. P-values
o0.05 were considered to be statistically significant.
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